Darzalex (daratumumab) vs Sarclisa (isatuximab)
Darzalex (daratumumab) vs Sarclisa (isatuximab)
Darzalex (daratumumab) and Sarclisa (isatuximab) are both monoclonal antibodies used to treat multiple myeloma, but they bind to different epitopes of the CD38 molecule on myeloma cells. Darzalex has been available since 2015 and has a well-established safety and efficacy profile, with various dosing schedules and combinations approved for use in different stages of the disease. Sarclisa was approved more recently, in 2020, and may be considered for patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor; it is also used in combination with other drugs and has shown efficacy in clinical trials. The choice between these medications should be made in consultation with a healthcare provider, taking into account the individual's specific medical history, treatment goals, and potential side effects.
Difference between Darzalex and Sarclisa
Metric | Darzalex (daratumumab) | Sarclisa (isatuximab) |
---|---|---|
Generic name | daratumumab | isatuximab |
Indications | Multiple myeloma | Multiple myeloma |
Mechanism of action | CD38-directed cytolytic antibody | CD38-directed cytolytic antibody |
Brand names | Darzalex | Sarclisa |
Administrative route | Intravenous | Intravenous |
Side effects | Infusion reactions, neutropenia, thrombocytopenia, fatigue, nausea, etc. | Infusion reactions, neutropenia, pneumonia, upper respiratory tract infection, diarrhea, etc. |
Contraindications | Hypersensitivity to daratumumab or any of its components | Hypersensitivity to isatuximab or any of its components |
Drug class | Monoclonal antibody | Monoclonal antibody |
Manufacturer | Janssen Biotech, Inc. | Sanofi |
Efficacy
Darzalex (Daratumumab) Efficacy in Multiple Myeloma
Darzalex (daratumumab) is a monoclonal antibody that targets the CD38 molecule found on the surface of multiple myeloma cells. As an immunotherapy, it works by enabling the immune system to detect and destroy the cancer cells. Darzalex has shown significant efficacy in the treatment of multiple myeloma, particularly when used in combination with other therapies. Clinical trials have demonstrated that Darzalex, when combined with standard-of-care treatments, can result in deeper and more durable responses compared to the standard treatments alone. This includes improvements in overall survival rates and progression-free survival among patients with relapsed or refractory multiple myeloma.
Sarclisa (Isatuximab) Efficacy in Multiple Myeloma
Sarclisa (isatuximab) is another monoclonal antibody that targets the CD38 protein on myeloma cells, similar to Darzalex. It is used in the treatment of adults with relapsed or refractory multiple myeloma. Sarclisa has been shown to be effective when used in combination with pomalidomide and dexamethasone, for patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Clinical studies have indicated that this combination with Sarclisa can lead to a significant reduction in the risk of disease progression or death. The efficacy of Sarclisa in improving progression-free survival has been a promising development in the management of multiple myeloma.
Comparing Darzalex and Sarclisa in Clinical Settings
Both Darzalex and Sarclisa have demonstrated efficacy in the treatment of multiple myeloma, particularly in the relapsed or refractory setting. The choice between these two treatments often depends on various factors, including patient-specific considerations, prior treatments, and the specific combination of drugs used alongside the monoclonal antibody. While direct head-to-head comparison data may be limited, both drugs have individually shown to improve patient outcomes in clinical trials. Physicians consider the unique profile of each patient when deciding on the use of Darzalex or Sarclisa as part of a treatment regimen.
Conclusion
In conclusion, Darzalex and Sarclisa have both emerged as important components in the treatment arsenal against multiple myeloma. Their efficacy in improving survival outcomes and delaying disease progression has been substantiated through various clinical trials. As research continues, these treatments may be further optimized, potentially in combination with other emerging therapies, to enhance their therapeutic benefits for patients with multiple myeloma. It is important for healthcare providers to stay informed about the latest evidence to make the best treatment decisions for their patients.
Regulatory Agency Approvals
Darzalex
Sarclisa
Access Darzalex or Sarclisa today
If Darzalex or Sarclisa are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us